Hypofibrinolytic state in HIV-1-infected patients treated with protease inhibitor-containing highly active antiretroviral therapy

Journal of Acquired Immune Deficiency Syndromes

Volumn 29, Issue 5, 2002, Pages 441-449

  Koppel, Kristina ^a   Bratt, Göran ^a   Schulman, Sam ^a   Bylund, Håkan ^a   Sandström, Eric ^a  

^a STOCKHOLM SÖDER HOSPITAL   (Sweden)

Author keywords

Fibrinogen; HIV Protease inhibitors (PIs); Insulin resistance; Lipodystrophy; Metabolic syndrome (MSDR); Plasminogen activator inhibitor type 1 (PAI 1)

Indexed keywords

ABACAVIR; FIBRINOGEN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDINAVIR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NELFINAVIR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TRIACYLGLYCEROL;

ADIPOSE TISSUE; ADULT; ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; BODY FAT; BODY MASS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GLUCOSE BLOOD LEVEL; HEMOSTASIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOFIBRINOLYSIS; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; ISCHEMIC HEART DISEASE; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SUBCUTANEOUS TISSUE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0036236967     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-200204150-00003     Document Type: Article

References (49)

1. Visceral abdominal-fat accumulation associated with use of indinavir
2. Disorders of fat distribution in HIV infection
3. Indinavir-associated lipodystrophy
4. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients
5. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
6. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance
7. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidemia, and diabetes mellitus: A cohort study
8. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors
9. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: Preliminary results of the LIPOCO study
10. Fat distribution and metabolic changes in patients with HIV infection
11. Serum lipid levels associated with increased risk for cardiovascular disease are associated with highly active antiretroviral therapy (HAART) in HIV-1 infection
12. HIV-associated lipodystrophy syndrome
13. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors
14. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy
15. Banting lecture 1988. Role of insulin resistance in human disease
16. Metabolic disturbances in hypertension: Results from the population study "Men Born in 1913."
17. Prevalence of the metabolic syndrome in drug-treated hypertensive patients and control subjects
18. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation
19. The metabolic syndrome, LDL particle size, and atherosclerosis. The Atherosclerosis and Insulin Resistance (AIR) Study
20. Factor XIII-mediated cross-linking of NH2-terminal peptide of alpha 2-plasmin inhibitor to fibrin
21. Plasminogen activator inhibitor 1: Development of a radioimmunoassay and observations on its plasma concentration during venous occlusion and after platelet aggregation
22. Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance
23. Plasminogen-activator inhibitor type 1 and coronary artery disease
24. Increased plasminogen activator inhibitor activity in noninsulin dependent diabetic patients-relationship with plasma insulin
25. Increased plasma plasminogen activator inhibitor I levels. A possible link between insulin resistance and atherothrombosis
26. Glucocorticoids and insulin promote plasminogen activator inhibitor 1 production by human adipose tissue
27. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study
28. Fibrinolytic variables and cardiovascular prognosis in patients with stable angina pectoris treated with verapamil or metoprolol. Results from the Angina Prognosis Study in Stockholm
29. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris
30. Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM Study in healthy men
31. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction
32. Haemostatic function and ischaemic heart disease: Principal results of the Northwick Park Heart Study
33. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: Evidence for the fibrinolytic system as an independent primary risk factor
34. Relationship between plasma fibrinogen and coronary heart disease in women
35. Fibrinogen as a cardiovascular risk factor: A meta-analysis and review of the literature
36. Prospective study of hemostatic factors and incidence of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) Study
37. Fibrinogen as a risk factor for coronary heart disease and mortality in middle-aged men and women. The Scottish Heart Health Study
38. Antithrombin III and fibrinogen as predictors of cardiac events in patients with angina pectoris
39. Severe premature coronary artery disease with protease inhibitors
40. Severe coronary disease in a young HIV-infected man with no cardiovascular risk factor who was treated with indinavir
41. Sudden cardiac death in a patient on 2 years highly active antiretroviral treatment (HAART) - A case report
42. Portal vein thrombosis in patients receiving indinavir, an HIV protease inhibitor
43. Premature lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitors
44. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy
45. Circulating interferon-alpha levels and hypertriglyceridemia in acquired immunodeficiency syndrome
46. Human immunodeficiency virus type I-related transient neurological deficits
47. Deep venous thrombosis in patients with AIDS
48. Insulin sensitivity and insulin clearance in human immunodeficiency virus-infected men
49. Impaired fibrinolysis in coronary artery disease